编者按：四十年 栉风沐雨，羊城 饲界潮涌珠江。 改革开放以来， 广州饲料产业乘 王胜林：从技术 营销到健康战 略，新南都精耕 机体抗氧化与营 养造血┃穗风不 惑_南方+_南方 plus 势而上，谱写奋 进史诗。依托技 术创新，穗风动 物营养星火燎 原，从本土走向 世界。浪潮之 中，广州市饲料 行业协会激荡四 十年，成为行业 发展标杆。为总 结协会及广州饲 料行业发展成 果，洞察行业走 势，南方农村报 推出"穗风·不 惑"系列报道。 以协会为镜，观 行业之变；以广 州为窗，察饲界 之势。敬请垂 注。 "饲料行业内卷 的根源是产能过 剩与产品同质 化。"广东新南 都饲料科技有限 公司（简称"新 南都"）常务副 总经理王胜林表 示，未来国家应 该通过政策引导 和资源统筹配 置，让行业走向 更良性的发展道 路。 从预混料到功能 性饲料添加剂， 从技术营销到健 康战略，新南都 的转型之路映射 着中国饲料工业 的升级轨迹。在 此背景下，王胜 林亲历了广州饲 料行业从技术拓 荒到行业转型升 级的蜕变。面对 当前畜牧业深度 调整期，以新南 都为代表的功能 性添加剂产业将 在行业绿色转型 中做出更多积极 探索。 广东新南都饲料 ...

冯定远：从全面 领先到平稳发 展，广州饲料行 业历经四大阶段 ┃穗风不惑_南 方+_南方plus 编者按：四十年 栉风沐雨，羊城 饲界潮涌珠江。 改革开放以来， 广州饲料产业乘 势而上，谱写奋 进史诗。依托技 术创新，穗风动 物营养星火燎 原，从本土走向 世界。浪潮之 中，广州市饲料 行业协会激荡四 十年，成为行业 发展标杆。为总 结协会及广州饲 料行业发展成 果，洞察行业走 势，南方农村报 推出"穗风·不 惑"系列报道。 以协会为镜，观 行业之变；以广 州为窗，察饲界 之势。敬请垂 注。 "40年企业不 易，40年协会更 难得。"广州市 饲料行业协会荣 誉会长、华南农 业大学教授冯定 远谈及协会的历 史，深有感触。 1986年，冯定远 从华南农业大学 硕士毕业，隔年 起在基层饲料企 业做技术推广。 彼时广州市饲料 协会（现广州市 饲料行业协会） 处于初创时期， 渴望吸纳青年人 才。1990年，冯 定远加入协会， 随后深度参与协 会技术工作，曾 任协会理事、副 秘书长、常务副 会长，2018年至 今任广州市饲料 行业协会荣誉会 长。 在他眼中，协会 参与和见证了中 国饲料工业的转 型巨变，从改革 开放遍地黄金 ...

证券代码：301156 证券简称：美农生物 上海美农生物科技股份有限公司 投资者关系活动记录表 编号：2026-01 投资者关系 活动类别 特定对象调研 □媒体采访 □新闻发布会 现场参观 其他 分析师会议 业绩说明会 □路演活动 电话会议 参与单位名称 远希私募、绅徽投资、山西证券 时间 2026 年 1 月 29 日 地点 公司会议室 上市公司接待 人员姓名 董事会秘书：张维娓 投资者关系活动 主要内容介绍 本次活动主要交流内容如下： 一、董事会秘书简要介绍公司概况 二、互动交流问答环节： 1. 公司境内外业务占比情况如何？未来业务拓展计划是 什么？ 答： 根据公司《2025 年半年度报告》披露的数据可以看出，公 司境内业务营业收入占比 60%多，境外业务营业收入占比接 近 40%。 未来，公司继续执行"深耕国内市场、突破国际市场"的 市场战略。在国内市场，将积极实施变革创新，通过拓宽 种类市场、做深客户市场、做强核心产品，发挥公司在国 内市场的客户资源、产品与服务能力、营销网络、品牌等 优势，继续做强做大。在海外市场，公司重点突破"一带 一路"沿线国家市场，坚持"走出去、请进来"的市场开 | 发策略，持 ...

Core Viewpoint - Meino Bio's stock performance shows a slight increase, with significant financing activity indicating a high level of investor interest and engagement in the company's shares [1][2]. Financing Summary - On January 26, Meino Bio's financing buy-in amounted to 4.726 million yuan, while financing repayment was 6.1917 million yuan, resulting in a net financing buy-in of -1.4656 million yuan [1]. - The total financing and securities balance for Meino Bio reached 48.3309 million yuan, representing 1.75% of its circulating market value, which is above the 50th percentile level over the past year, indicating a relatively high financing balance [1]. - The company had no short selling activity on January 26, with a short selling balance of 27,500 yuan and a remaining short selling volume of 1,400 shares, which is above the 90th percentile level over the past year, indicating a high level of short interest [1]. Business Performance - As of September 30, Meino Bio reported a total of 10,400 shareholders, a decrease of 17.92% from the previous period, while the average circulating shares per person increased by 21.83% to 7,161 shares [2]. - For the period from January to September 2025, Meino Bio achieved operating revenue of 390 million yuan, reflecting a year-on-year growth of 14.68%, and a net profit attributable to shareholders of 40.9182 million yuan, which is a 29.44% increase year-on-year [2]. Dividend and Shareholding - Since its A-share listing, Meino Bio has distributed a total of 168 million yuan in dividends [3]. - As of September 30, 2025, among the top ten circulating shareholders, the Guotai CSI Animal Husbandry ETF ranked as the sixth largest shareholder with 1.1559 million shares, an increase of 334,500 shares from the previous period [3]. - The Nuoan Multi-Strategy Mixed A fund entered as a new shareholder, holding 861,800 shares, while the Jianxin Flexible Allocation Mixed A fund also entered as a new shareholder with 448,700 shares [3].

Group 1: Company Overview and Strategy - The company adheres to the value proposition of "product leadership, value service, and partner growth," focusing on product, market, customer, and efficiency [2] - The company has established a nationwide marketing network in China and a professional marketing and technical service team to provide valuable products and solutions [3] - The company has been operating internationally for over 20 years, developing a mature method for selecting quality distributors and a unique "partner growth" model [4] Group 2: Financial Performance and Revenue Structure - The company's overseas business revenue accounts for nearly 40% of total revenue, indicating rapid growth in international markets [3] - The main customers include feed production enterprises, breeding enterprises, and distributors, with notable clients such as New Hope and Tongwei [3] Group 3: Product Development and R&D - The core products include functional feed additives, nutritional feed additives, and enzymatic plant proteins, with functional feed additives generating the highest revenue [5] - The company aims to develop high-efficiency, safe, and environmentally friendly feed additives and enzymatic protein products to address industry pain points and enhance animal production performance [5] Group 4: Market Expansion and Future Plans - The company has established sales networks in over 40 countries, including Vietnam, Russia, and Brazil, and plans to continue expanding its international presence [4] - The company is developing a corn protein processing project with an expected annual output of 100,000 tons, which will diversify its product offerings and mitigate market risks [6] Group 5: Collaborations and Research Initiatives - The company collaborates with various universities and research institutions to enhance its research capabilities and support product innovation [7] - Ongoing research projects focus on non-antibiotic disease prevention in poultry and improving the efficiency of fish feed, contributing to sustainable aquaculture [7] Group 6: Market Position and Future Outlook - The company is exploring opportunities in the pet market and is open to potential mergers and acquisitions, depending on industry trends and long-term strategic planning [8] - The company emphasizes a dual approach of expanding into new markets while deepening existing market value [4]

Group 1 - The core point of the article highlights the recent performance of Meino Biological, which saw a stock price increase of 6.99%, reaching 20.36 CNY per share, with a total market capitalization of 2.866 billion CNY [1] - Meino Biological specializes in the research, production, and sales of feed additives and enzymatic protein feed materials, with its main business revenue composition being functional feed additives (58.94%), nutritional feed additives (21.25%), enzymatic protein feed materials (13.33%), concentrated feed (5.53%), and others (0.94%) [1] Group 2 - From the perspective of major circulating shareholders, Guotai Fund's ETF, Guotai Zhongzheng Livestock Breeding ETF (159865), increased its holdings by 334,500 shares, now holding a total of 1,155,900 shares, which accounts for 1.55% of the circulating shares [2] - The Guotai Zhongzheng Livestock Breeding ETF has a current scale of 6.097 billion CNY, with a year-to-date return of 14.49% and a one-year return of 12.63% [2]

Group 1 - The core viewpoint of the news highlights the recent performance and financial metrics of Meino Biological, including stock price movement and trading volume [1] - On October 13, Meino Biological's stock rose by 2.70%, with a trading volume of 253 million yuan, and a net financing purchase of 6.27 million yuan [1] - The total financing and securities balance for Meino Biological reached 54.91 million yuan, accounting for 3.39% of its circulating market value, indicating a high level compared to the past year [1] Group 2 - As of June 30, the number of shareholders for Meino Biological increased to 12,700, a rise of 74.14%, while the average circulating shares per person decreased by 33.43% [2] - For the first half of 2025, Meino Biological reported a revenue of 236 million yuan, representing a year-on-year growth of 13.69%, and a net profit attributable to shareholders of 23.53 million yuan, up 17.68% year-on-year [2] Group 3 - Since its A-share listing, Meino Biological has distributed a total of 154 million yuan in dividends [3] - As of June 30, 2025, the seventh largest circulating shareholder of Meino Biological is the Guotai Zhongzheng Livestock Breeding ETF, holding 821,400 shares as a new shareholder [3]

Group 1: Report Basics - The report is about a research on Meinong Bio-tech, belonging to the agriculture, animal husbandry, feed, and fishery industry, with a research date of September 23, 2025 [1][16] - The listed company's reception staff includes the board secretary Zhang Weiwei and the head of the international marketing center, Hu Yanlingjun [16] Group 2: Research Institutions - The research institutions include securities companies such as Huatai Securities, Caitong Securities, Yuekai Securities, Huaxin Securities, and others like Hong Kong Dongjian International Securities, Xiaofeng Fund, and Fuzhijia Investment [17] - The proportion of securities companies among the research institutions is 46%, others 38%, law firms 8%, and investment companies 8% [20] Group 3: Core Views - The company adheres to the market strategy of "deeply cultivating the domestic market and breaking through the international market" and aims to become a globally leading animal nutrition technology company [23] - The company has a rich product line, a mature overseas dealer management model, and a set of core technologies, and it will continue to invest in international market development and new product R & D [23][27] Group 4: Company Business Analysis International Business - The company's international business has a first - mover advantage, with a sales network covering more than 40 countries and regions. It will continue to expand the international market through a two - pronged approach of "going out" and "digging deep" [23][25] - The overseas business income has maintained a growth rate of over 20% and accounts for nearly 40% of the total revenue. It adopts a sales model of "mainly distribution, supplemented by direct sales" [25] - The company has a mature overseas dealer management and selection model and manages exchange - rate risks through foreign exchange hedging [26] Core Technologies - The company has mastered core technologies such as formulation technology, preparation technology, and enzymatic hydrolysis technology, and continuously optimizes the process path design [27] Product Layout - The company's products include functional feed additives, nutritional feed additives, and enzymatic hydrolysis plant protein feed raw materials. It will launch corn - related products after the "100,000 - ton corn protein finishing project" is put into production [28][30] Talent Management - The company has built a "dual - wheel drive" talent management system of "internal self - cultivation and external talent introduction" and launched an equity incentive project and the "Meinong Academy" [30][31] Project Investment - The "100,000 - ton corn protein finishing project" is in line with national policies, which can improve the utilization rate of corn protein and create greater commercial value. Product prices will be determined by multiple factors [31][33][34]

Group 1: Company Overview and Market Strategy - The company aims to become a global leader in animal nutrition technology, with a market strategy focused on "deepening domestic and breaking through internationally" [2] - The company has established a sales network covering over 40 countries and regions across Asia, Europe, Africa, South America, and Oceania, leveraging a distributor-centric model for international market expansion [3][4] - The company has maintained a growth rate of over 20% in its overseas business, with overseas revenue accounting for nearly 40% of total revenue [4] Group 2: International Market Expansion Initiatives - The company plans to focus on markets along the "Belt and Road" initiative, utilizing localized operations and technological innovation to build a competitive edge [3] - Key initiatives include developing new markets, deepening existing market value, and enhancing product lines based on customer needs [3] - The company emphasizes participation in international industry exhibitions to increase visibility and strengthen its international market image [3] Group 3: Financial Management and Risk Control - The company has developed a mature overseas distributor selection and management model over 20 years, focusing on credit policies and risk management [5] - It closely monitors macroeconomic conditions and adjusts sales strategies to mitigate risks, including currency risk through hedging [5] Group 4: Core Technologies and Product Development - The company has established a robust R&D system, focusing on core technologies such as formulation, preparation, and enzymatic technologies [6][7] - It aims to develop high-efficiency, safe, and environmentally friendly feed additives and enzymatic protein feed materials, with a focus on meeting diverse customer needs [8] - The upcoming "annual production of 100,000 tons of corn protein processing project" will introduce new products to alleviate domestic protein resource shortages [9][10] Group 5: Talent Management and Organizational Development - The company implements a dual-driven talent management system, focusing on internal development and external recruitment to support sustainable growth [8] - Initiatives include a stock incentive program and the establishment of "Meinong Academy" for comprehensive talent development [8]

Group 1 - The core viewpoint of the news highlights the financial performance and market activity of Meino Biological, indicating a positive trend in revenue and net profit growth [2][3] - As of August 28, Meino Biological's stock price increased by 2.19%, with a trading volume of 93.57 million yuan, and a net financing purchase of 1.43 million yuan [1] - The company has a total financing and securities balance of 46.28 million yuan, which accounts for 2.83% of its circulating market value, indicating a relatively high level compared to the past year [1] Group 2 - For the first half of 2025, Meino Biological reported a revenue of 236 million yuan, representing a year-on-year growth of 13.69%, and a net profit attributable to shareholders of 23.53 million yuan, up 17.68% year-on-year [2] - The company has distributed a total of 154 million yuan in dividends since its A-share listing [3] - As of June 30, 2025, the number of shareholders increased to 12,700, with an average of 5,878 circulating shares per person, a decrease of 33.43% from the previous period [2]